The expert panel provides clinical insights on treating patients with high-risk or locally advanced triple-negative breast cancer.
DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer
Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease
Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.